Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label study of PTI5803 plus probenecid in drug-resistant seizures due to focal cortical dysplasia
2026-525162-21-00Phase 2Authorised
- Sponsor
- Panntherapi
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pti5803 in cortical dysplasia (FCD), sponsored by Panntherapi. Primary endpoints: Safety and tolerability (TEAEs and SAEs), Safety: vital signs, labs, physical exam, ECG and 2 more. Planned start Jul 2026; status: authorised.
02
Drugs
pti5803
03
Conditions
cortical dysplasia (FCD)
Beyond the preview
Go deeper on 2026-525162-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525162-21-00.